NeuroOne®: Revolutionizing Neurosurgery with Thin-Film Electrode Technology

NeuroOne Medical Technologies Corporation (NMTC) is set to present at the Oppenheimer 35th Annual Healthcare MedTech Conference, offering investors an opportunity to learn about its innovative thin-film electrode technology and its potential to transform neurosurgery. The company's unique platform is designed to advance a new era in neuroscience, focusing on minimally invasive and high-definition electrodes for diagnostic and therapeutic neurological applications.



NeuroOne's thin-film electrode technology differentiates it from competitors in the neurotech market by offering several advantages to both patients and healthcare providers. The company's electrodes are designed to be thin, flexible, and high-resolution, making them ideal for minimally invasive procedures. This design allows for improved mapping capabilities, better surgical implant options, and a decreased risk of infection. Additionally, NeuroOne's technology has demonstrated the potential to provide chronic stimulation at typical stimulation parameters, making it suitable for long-term use in treating conditions such as chronic back pain due to failed back surgeries.

The potential market size and growth rate for NeuroOne's products are significant, driven by the increasing prevalence of neurological disorders and the demand for minimally invasive and high-definition diagnostic and therapeutic devices. The neurotech devices market is expected to grow at a CAGR of 16.7% during the forecast period, reaching USD 42.1 billion by 2032. NeuroOne's platform technology is intended to address various markets, representing a substantial opportunity. For instance, the potential revenue from using electrode-related technology for surgical candidates with epilepsy is estimated to be $5 billion, while the potential revenue from using electrodes in surgery for brain tumor patients is estimated to be an additional $240 million. NeuroOne's platform technology is expected to address other markets such as Parkinson's Disease, Pain due to failed back surgery(ies), and ablation of brain tissue for epilepsy and brain tumors, collectively representing a market opportunity already estimated to be over $2 billion worldwide.

NeuroOne's partnership with Mayo Clinic and its licensed patents from Wisconsin Alumni Research Foundation (WARF) significantly contribute to its competitive position and long-term success. Mayo Clinic's partial ownership and involvement in NeuroOne's development process have provided valuable clinical validation, while WARF's patent licensing has given NeuroOne access to a robust intellectual property portfolio. This intellectual property provides NeuroOne with a competitive advantage by protecting its innovative electrode technology and allowing it to differentiate itself from competitors. Additionally, NeuroOne's patented technology leverages printed circuit technology for minimally invasive treatments, expected to reduce both manufacturing and procedural costs while simultaneously improving patient outcomes.

In conclusion, NeuroOne's presentation at the Oppenheimer 35th Annual Healthcare MedTech Conference offers investors an opportunity to learn about its innovative thin-film electrode technology and its potential to revolutionize neurosurgery. With its unique platform, strategic partnerships, and significant market opportunity, NeuroOne is well-positioned to capitalize on the growing demand for minimally invasive and high-definition diagnostic and therapeutic devices in the neurotech market.